Latest findings surround patient trials U3-1287 and U31287, assessing patritumab deruxtecan for this management of late-stage female cancer. Early information shown at the medical meeting demonstrates modest positive response, though difficulties remain regarding optimal administration and individual choice. More analysis are ongoing to fully under